Video

Dr. Moses On Ongoing Trials in mHSPC

Author(s):

Kelvin Alexander Moses, MD, PhD

In Partnership With:

Kelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.

Kelvin Alexander Moses, MD, PhD, associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer (mHSPC).

Combination strategies are currently under investigation, says Moses. Additionally, checkpoint inhibitors are being explored in men with specific alterations, such as BRCA mutations.

During the 2019 OncLive® State of the Science Summit™ on Genitourinary Malignancies, Kirk A. Keegan, MD, MPH, spoke about advanced diagnostic imaging modalities, says Moses. Advanced imaging may allow for earlier detection and intervention of metastatic prostate cancer. However, further research is needed to determine if there is a comparable survival advantage with earlier treatment exposure as with current approved agents, concludes Moses.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
Related Content
Philip Sutera, MD, of Johns Hopkins University School of Medicine
May 30th 2024

PSMA Response Is Associated With MFS Improvement in Oligometastatic CSPC

Carrie L. Kitko, MD, associate professor, pediatrics, medical director, the Pediatric Stem Cell Transplantation Program, the Ingram Professor of Pediatric Oncology, Monroe Carell Jr. Children’s Hospital at Vanderbilt; Sagar S. Patel, MD, director, Communications and Media Relationships, the Division of Hematology, the University of Utah Huntsman Cancer Institute
February 19th 2024

Kitko and Patel Emphasize the Importance of GVHD Research and Awareness

FDA
May 28th 2024

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Muhamed Baljevic, MD, FACP
May 25th 2024

First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

Katie S. Gatwood, PharmD, BCOP, a clinical pharmacist specialist in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center
May 24th 2024

Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies